Immunotherapeutic approaches of severe sepsis and septic shock: Where are we, and where do we go from here?

Intensivmedizin und Notfallmedizin

Volumn 34, Issue 6, 1997, Pages 527-537

  Martin, C ^a   Viviand, X ^a   Arnaud, S ^a   Boisson, C ^a  

^a HÔPITAL NORD   (France)

Author keywords

Cytokines; Immunomodulation; Platelet activating factor; Septic shock; Severe sepsis

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; ANTIOXIDANT; ANTITHROMBIN III; BRADYKININ ANTAGONIST; CENTOXIN; CORTICOSTEROID; CYTOKINE; DOPAMINE; EDOBACOMAB; ENDOTOXIN ANTIBODY; GAMMA INTERFERON; GLYCOLIPID; HEPARIN; ICOSANOID; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; PENTOXIFYLLINE; POLYCLONAL ANTIBODY; PROTEINASE INHIBITOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG;

CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; HYPOTENSION; IMMUNOMODULATION; IMMUNOTHERAPY; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 0030868501     PISSN: 01753851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003900050081     Document Type: Review

References (77)

1. Bone RC (1991) Sepsis, the sepsis syndrome, multiple organ failure: a plea for comparable definitions. Ann Intern Med 114:332-333
2. Centers for Disease Control (1990) Increase in national hospital discharge survey rates for septicemia. Morbidity and Mortality Weekly Report 39:31-34
3. Ziegler EJ, Mc Cutchan JA, Fierer J, Glauser MP et al. (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225-1230
4. Ziegler EJ, Fisher CJ, Sprung CL et al. (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 324:429-436
5. Sprung CL, Caralis PV, Martial EH et al. (1984) The effects of high dose corticosteroids in patients with septic shock. N Engl J Med 311:1137-1143
6. Kaufman BS, Rackow EC, Falk JL (1984) The relationship between oxygen delivery and consumption during fluid resuscitation of hypovolemic and septic shock. Chest 85:336-340
7. Veterans Administration Systems Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659-665
8. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Denarello CA, Cerai A, Wolff SM, Wilmore DW (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481-1486
9. Baumgartner JD, Glauser MP (1987) Controversies in the use of passive immunotherapy for bacterial infections in the critically ill patient. Rev Infect Dis 9:194-205
10. Zinner SH, Mc Cabe WR (1976) Effects of IgM and IgG antibody in patients with bacteremia due to gramnegative bacilli. J Infect Dis 133:37-45
11. Lachman E, Pitsoe SB, Gaffin SL (1984) Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetrical and gynaecological origin. Lancet 1:981-983
12. Fomsgaard A, Back L, Fomsgaard JS, Engquist A (1989) Preliminary study on treatment of septic shock patients with antilipopolysaccharide IgG from blood donors. Scand J Infect Dis 21:697-708
13. Schedel I, Dreikhaussen U. Neutwig B et al. (1991) Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 19:1104-1113
14. Mc Cutchan JA, Wolf JL, Ziegler EJ, Brande AI (1988) Ineffectiveness of single-dose human antiserum to core glycolipid (Escherichia coli 15) for prophylaxis of bacteremic, gram-negative infection in patients with prolonsed neutropenia. Schw Mediz Woch 113 suppl: 40-45
15. Baumgartner JD, Glauser PG, Mc Cutchan JA, et al. (1985) Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 2:59-63
16. J5 Study Group (1992) Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double blind study. J Infect Dis 165:695-701
17. Calandra T, Glauser MP, Schellekens J, Verhoef J and the Switt-Dutch J5 Immunoglobulin Study Group (1988) Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis 158:312-319
18. The Intravenous Immunoglobulin Collaborative Study Group (1992) Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharidic immune globulin in patients at risk of postsurgical infection. N Engl J Med 327:234-240
19. Calandra T, Baumgartner JD (1995) Anti-endotoxin therapy. In: Critical trials for the treatment of sepsis. Update in Intensive Care and Emergency Medicine, 19. Sibbald WJ, Vincent JL (eds), Springer, Berlin, 1 vol, 406 p, pp 237-250
20. Baumgartner JD, Heumann D, Glauser MP (1991) The HA-1A monoclonal antibody for gram-negative sepsis. N Engl J Med (Letter) 325:281-282
21. Luce JM (1993) Introduction of newtechnology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Crit Care Med 21:1233-1241
22. Siegel JP, Stein KE, Zoon KC (1992) Anti-endotoxin monoclonal antibodies (the FDA reply). N Engl J Med 327:890-891
23. Wenzsl RP (1992) Anti-endotoxin monoclonal antibodies. A second look. N Engl J Med 326:1151-1153
24. Wenzel RP, Andriole T, Bartlett JG (1992) Antiendotoxin monoclonal antibodies for gram-negative sepsis: guidelines from the Infectious Disease Society of America. Clin Infect Dis 14:973-976
25. Ziegler EJ, Smith CR (1992) Anti-endotoxin monoclonal antibodies. N Engl J Med (Letter) 326:1165
26. Mc Closkey RV, Straube RC, Sanders C, Smith CR and the CHESS Trial Study Group (1994) Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial period. Ann Intern Med 121:1-5
27. Anonyme (1994) The French national registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. Arch Intern Med 154:2484-2491
28. Kett DH, Quartin AA, Sprung CL et al. (1994) An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody. Crit Care Med 22:1227-1234
29. Greenmam RL, Schein RMH, Martin MA et al. (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097-1102
30. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD et al. (1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23:994-1006
31. st ICAAC Chicago No 1170, p 294
32. Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ (1992) Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected serious gram-negative sepsis. Crit Care Med 20:730-735
33. Morrison DC, Silverstein R, Parmely MJ (1992) Novel approaches to the treatment of septic shock. In: Vincent JL (ed) Yearbook of Intensive Care and Emergency Medicine. Springer, Berlin, 1 Vol, pp 91-103
34. Proctor RA, Will JA, Burhop KE, Raetz CRH (1986) Protection of mice against lethal endotoxemia by a lipid A precursor. Infect Immun 52:905-907
35. Marra MN, Thornton MB, Snable JL (1994) Endotoxin-binding and neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med 22:559-565
36. Fisher CJ Jr, Marra MN, Palardy JE (1994) Human neutrophil bactericidal/ permeability-increasing protein reduces mortality rate from endotoxin challenge. A placebo-controlled study. Crit Care Med 22:553-558
37. Dofferhoff ASM, Vellenga E, Limburg PC et al. (1991) Tumor necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature. Neth J Med 39:45-62
38. Hesse DG, Tracey KJ, Fong Y, et al. (1988) Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 166:147-153
39. Tracey KJ, Vlasara H, Cerami H (1989) Cacnectin/tumor necrosis factor. Lancet 1:1122-1126
40. Beutler B, Cerami A (1986) Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320:584-588
41. Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316:379-385
42. Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871
43. Tracey KJ, Beutler B, Lowry SF et al. (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470-473
44. Mathison JC, Wolfson E, Ulevitch RJ (1988) Participation of tumor necrosis factor in the mediation of gram-negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 81:1925-1937
45. Silva AT, Bayston KF, Cohen J (1990) Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimental gram-negative shock. J Infect Dis 162:421-427
46. Tracey KJ, Fong Y, Hesse DG et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662-664
47. Hinshaw LB, Tekamp-Olson P, Chang ACK et al. (1990) Survival of primates in LD 100 septic shock following therapy with antibody to tumor necrosis factor (TNFα). Circ Shock 30:279-292
48. Opal SM, Cross AS, Kelly NM et al. (1990) Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis 161:1148-1152
49. st ICAAC Chicago No 538
50. Wayne J, Silva A, Cohen J (1991) Role of tumor necrosis factor (TNF) in experimental gram positive sepsis. 31st ICAAC Chicago no 789
51. Bagdy GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S (1991) Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of septic shock. J Infect Dis 163:83-88
52. st ICAAC Chicago p 294 No 790
53. st ICAAC Chicago No 540
54. Opal SM, Cross AS, Sadoff JC et al. (1991) Efficacy of antilipopoly saccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic model of Pseudomonas sepsis. J Clin Invest 88:885-890
55. Franks AK, Kujawa KI, Yaffe LJ (1991) Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival. Infect Immun 59:2609-2614
56. Silva AT, Appelmelk BJ, Baurman WA, Bayston KF, Cohen J (1990) Monoclonal antibody to endotoxin core protects mice from Escherichia coli sepsis by a mechanisms independent of tumor necrosis factor and interleukine 6. J Infect Dis 162:454-459
57. Exley AR, Cohen J, Buurman W, Owen R, Lumley J, Hanson G, Aulakh JM, Bodmer M, Stephens S, Ridell A, Perry M (1990) Monoclonal antibody to TNF in severe septic shock. Lancet 2:1275-1277
58. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P et al. (1994) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21:318-327
59. Dhainaut JF, Vincent JL, Richard C, Stephens S, Lejeune P, Martin C, Schlemmer B (1994) CDP 571, a CDR-grafted anti-human TNFα antibody in septic shock: safety, pharmacokinetics and influence on cytokine levels. Am J Resp Crit Care Med 149:A241
60. 2, a chimeric anti TNF antibody in patients with sepsis. Intensive Care Med 20:151
61. Boekstegers P, Weidenhofer S, Zell R, Pilz G, Holler E, Ertel W et al. (1994) Repeated administration of a F(ab′)2 fragment of an antitumor necrosis factor a monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels. Shock 1; 237-245
62. Reinhart K. Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D et al. (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195 F, in patients with sepsis and septic shock: a multicenter randomized, placebo-controlled, dose-ranging study. Crit Care Med 24:733-742
63. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 273:934-941
64. Cohen J, Carlet J for the INTERSEPT Study Group (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 24:1431-1440
65. Wherry J, Wenzel R, Wunderink R, Silverman H, Perl T, Nasraway S et al. (1993) Monoclonal antibody to human tumor necrosis factor (TNF mab): multicenter efficacy and safety in patients with the sepsis syndrome, 33rd ICAAC p 246 no 696
66. Fisher CJ, Agosti JM, Opal M, Lowry SF, Balk RA, Sadoff JC et al. (1996) Treatment of septic shock with tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 334:1997-1702
67. Van der Poll T, Lowry SF (1995) Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 3:1-12
68. Seckinger P, Lowenthal JW, Williamson K, Dayer JM, Mc Donald HR (1987) A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 139:1546-1549
69. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA (1991) A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 173:1029-1032
70. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550-552
71. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G et al. (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter study. Crit Care Med 22:12-21
72. Fisher JC Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman TJ et al. (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of patients with the sepsis syndrome. Results from a randomized, doubie-blind. placebo-controlled trial. JAMA 271:1836-1843
73. Starnes HF, Pearce MK, Tewari A, Yim JH, Zou J, Abrams JS (1990) Anti IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-α challenge in mice. J Immunol 145:4185-4191
74. Redmond HP, Chavin KD, Bromberg JS, Daly JM (1991) Inhibition of macrophage-activating cytokines is beneficial in the acute septic response. Ann Surg 214:502-509
75. Dhainaut JF, Tenaillon A, le Tulzo Y et al. (1994) Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22:1720-1728
76. Cross A (1996) Novel approaches to the treatment of sepsis: lessons learned and future directions. Shock 6:S71-S74
77. Verhoef J, Hustinx WMN, Frasa H et al. (1996) Issues in the adjunct therapy of severe sepsis. J Antimicrob Chemother 38:167-182